Gilead los­es key patent chal­lenge over best-sell­ing HIV drug

Gilead won’t eas­i­ly rid of it­self of this HIV patent chal­lenge.

Last year, the De­part­ment of Health and Hu­man Ser­vices said that it owned some of the patents for Gilead’s best-sell­ing HIV pre­ven­tion drug, Tru­va­da, al­so known as PrEP. Gilead re­spond­ed by ar­gu­ing in court that HHS’s patents were in­valid.

To­day, a US Patent and Trade­mark Of­fice pan­el ruled that Gilead was like­ly to lose its chal­lenge.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.